검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 20일
현재 선택: 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor ORR 14.9%·t½ ~1 week (SC) | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor ORR 1%·t½ 6 h |
|---|---|---|
Overview Program | Ozempic / Wegovy (semaglutide) | Mounjaro / Zepbound (tirzepatide) |
Overview Company | Novo Nordisk | Eli Lilly |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | GLP-1 receptor | GLP-1 / GIP receptor |
Overview Indication | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) | Type 2 diabetes, chronic weight management |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
MoA Mechanism | GLP-1R agonism → glucose-dependent insulin secretion, delayed gastric emptying, central satiety | Dual GIP/GLP-1R agonism → enhanced insulin secretion, weight loss, lipolysis |
MoA Biomarker | HbA1c, body weight, waist circumference | HbA1c, body weight, triglycerides |
PK/PD Half-life | ~1 week (SC) | 6 h |
PK/PD Species | Mouse, HbA1c, fasting glucose, weight | Mouse |
PK/PD Animal (cat.) | Mouse | Mouse |
PK/PD Experiment | pharmacokinetic | pharmacokinetic |
Toxicology Species | NHP, Mouse, Rat | Mouse, Rat |
Toxicology Animal (cat.) | NHP | Mouse, Rat |
Toxicology Major finding | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | — |
Toxicology CRS | N/A | — |
Clinical Primary efficacy | ORR 14.9% | ORR 1% |
Clinical ORR | Weight ↓14.9% vs placebo (STEP 1) | HbA1c ↓2.4% (SURPASS-2 vs semaglutide 1 mg) |
Clinical PFS | MACE benefit in SELECT (obesity + CVD) | Weight ↓20% at 72 wk (SURMOUNT-1) |
Clinical Result source | STEP 1 / SELECT | SURPASS-2 / SURMOUNT-1 |
Clinical Data Tier / Score | S · 75 | C · 70 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Dose / schedule | q1w SC (titrated) or oral daily | — |
Clinical Clinical sync | 2026년 7월 20일 (오늘) | 2026년 7월 20일 (오늘) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 20일
현재 선택: 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor ORR 14.9%·t½ ~1 week (SC) | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor ORR 1%·t½ 6 h |
|---|---|---|
Overview Program | Ozempic / Wegovy (semaglutide) | Mounjaro / Zepbound (tirzepatide) |
Overview Company | Novo Nordisk | Eli Lilly |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | GLP-1 receptor | GLP-1 / GIP receptor |
Overview Indication | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) | Type 2 diabetes, chronic weight management |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
MoA Mechanism | GLP-1R agonism → glucose-dependent insulin secretion, delayed gastric emptying, central satiety | Dual GIP/GLP-1R agonism → enhanced insulin secretion, weight loss, lipolysis |
MoA Biomarker | HbA1c, body weight, waist circumference | HbA1c, body weight, triglycerides |
PK/PD Half-life | ~1 week (SC) | 6 h |
PK/PD Species | Mouse, HbA1c, fasting glucose, weight | Mouse |
PK/PD Animal (cat.) | Mouse | Mouse |
PK/PD Experiment | pharmacokinetic | pharmacokinetic |
Toxicology Species | NHP, Mouse, Rat | Mouse, Rat |
Toxicology Animal (cat.) | NHP | Mouse, Rat |
Toxicology Major finding | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | — |
Toxicology CRS | N/A | — |
Clinical Primary efficacy | ORR 14.9% | ORR 1% |
Clinical ORR | Weight ↓14.9% vs placebo (STEP 1) | HbA1c ↓2.4% (SURPASS-2 vs semaglutide 1 mg) |
Clinical PFS | MACE benefit in SELECT (obesity + CVD) | Weight ↓20% at 72 wk (SURMOUNT-1) |
Clinical Result source | STEP 1 / SELECT | SURPASS-2 / SURMOUNT-1 |
Clinical Data Tier / Score | S · 75 | C · 70 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Dose / schedule | q1w SC (titrated) or oral daily | — |
Clinical Clinical sync | 2026년 7월 20일 (오늘) | 2026년 7월 20일 (오늘) |
추천 비교
추천 비교